<DOC>
	<DOCNO>NCT00195988</DOCNO>
	<brief_summary>Open label , randomise , prospective , onecentre Investigator Driven Study : Comparison two protocol immunosuppression liver Tx child : A : Study group - FK506-MMF . Immunosupression protocol : Methylprednisolone 10 mg/kg intraoperatively i.v . FK506 Day 0 1 orally ( 0,15 mg/kg/D two dos ) .MMF max . dosage 30 mg/kg/D p.o . day 0 day 90 . B . Control group - Tacrolimus , steroid . Immunosupression protocol : Methylprednisolone 10 mg/kg bm intraoperatively Children &lt; 25kg bm : Methylprednisolone taper 100 mg/D day 0 MP 10 mg day 7 Children &gt; 25kg bm : Methylprednisolone taper 200 mg/D day 0 MP 20 mg day 7 Week 2-4 Prednisone - 0,5-0,3 mg/kg/D ; Week 4-12 Prednisone –0,3-0,2 mg/kg/D ; Month 4-6 Prednisone 0,2 – 0,1 mg/kg/D Month 7 – Steroid withdrawal FK506 Day 0 1 orally ( 0,15 mg/kg/D two dos ) . Primary end point : Number rejection , number steroid-resistant rejection . Secondary end point : Patients graft survival Dyslipidemia one year transplantation Hypertension one year transplantation Hyperglycemia/Diabetes de novo one year transplantation Renal function Tx 1 year Tx</brief_summary>
	<brief_title>Comparison Immunosuppression Protocols After LTx Children</brief_title>
	<detailed_description>A : Study group FK506-MMF . Immunosupression protocol : Metylprednisolon 10 mg/kg intraoperatively i.v . FK506 Day 0 1 oraly ( 0,15 mg/kg/D two dos ) . MMF max . dosage 30 mg/kg/D p.o . day 0 day 90 accord patient condition therapeutic MMF blood concentration Tailoring : Immunosupression protocol tailor accord cause liver failure : patient autoimmune liver disease ( autoimmune hepatitis , PBC , PSC , overlap syndrome etc ) would maintain MMF . All recipient include cryptogenic liver cirrhosis gradually ( 1 month ) withdrawn MMF administration 90 day transplantation : 1. good kidney function ( S-creatinin &lt; 150 umol/l ) enable achieve maintain Tacrolimus trough level 6 ng/ml 2. one episode acute rejection graft resolve completely . Targeted Tacrolimus trough level : Month 1 - 3 level 10-15 ng/ml Month 4-6 10-12 ng/ml Month 7-12 10 – 6 ng/ml Rejection treatment : 1 . Tacrolimus dose adjustment upper limit target level last Tacrolimus trough level intend limit . 2 . Steroid bolus would administer Metylprednisolon 10 mg/kg daily 3 consecutive day . No steroid taper . Control biopsy normalisation LFTs . 3 . After two attack acute rejection MMF disontinuation Prednison dose would introduce least 0,3 mg/D 3 month . 4 . After second attack AR MMF discontinuation Prednison dose would introduce least 0,3 mg/D 6 month . 5 . Steroid resistant rejection : biopsy proven rejection persist three course steroid pulse . Steroid resistant rejection would treat accord local praxis . Concomitant drug : Antiviral antibacterial prophylaxis accord current centre praxis . Prophylaxis cholestasis prophylaxis/treatment bone disease applicable . B . Control group Tacrolimus , steroid . Immunosupression protocol : Metylprednisolon 10 mg/kg bm intraoperatively Children &lt; 25kg bm : Metylprednisolon taper 100 mg/D day 0 MP 10 mg day 7 Children &gt; 25kg bm : Metylprednisolon taper 200 mg/D day 0 MP 20 mg day 7 Week 2-4 Prednison - 0,5-0,3 mg/kg/D Week 4-12 Prednison –0,3-0,2 mg/kg/D Month 4-6 Prednison 0,2 – 0,1 mg/kg/D Month 7 – Steroid withdrawal FK506 Day 0 1 orally ( 0,15 mg/kg/D two dos ) . Intended Tacrolimus trough level : Month 1 –3 level 10-15 ng/ml Month 4-6 10-12 ng/ml Month 7-12 6-10 ng/ml Rejection treatment : 1 . Tacrolimus dose adjustment upper limit target level last Tacrolimus trough level intend limit . 2 . Steroid bolus would administer Metylprednisolon 10 mg/kg bm daily 3 consecutive day . No steroid taper , return previous steroid dose . Control biopsy normalisation LFTs . 3 . After two attack acute rejection Prednison dose would maintain least 0,3 mg/D 3 month . 4 . Steroid resistant rejection : biopsy proven rejection persist three course steroid pulse . Steroid resistant rejection would treat accord local praxis . Biopsy : Liver biopsy take suspicion graft rejection disease recurrence . Protocol biopsy would take accord local practice , liver biopsy one-year transplantation mandatory . Primary end point : Number rejection , number steroid-resistant rejection . Secondary end point : Patients graft survival Dyslipidemia one year transplantation Hypertension one year transplantation Hyperglycemia/Diabetes de novo one year transplantation Renal function Tx 1 year Tx Inclusion criterion : Subjects meet follow criterion eligible study : 1 . Male female patient , old 18 year old . 2 . Primary liver transplantation 3 . Patient capable understand purpose risk study inform orally write give informed consent Exclusion criterion : Subjects meet one follow criterion eligible study : 1 . Female patient pregnant breast feed 2 . Patients &gt; 18 year old 3 . Combined liver-kidney transplantation 4 . Recipient second liver graft 5 . Patients allergic , hyper-sensitive intolerant HCO-60 structurally related compound , macrolide antibiotic tacrolimus . 6 . Patients know HIV-anamnesis 7 . Patient require ongoing dose systemic immunosuppressive drug study entry another indication prophylaxis liver graft rejection 8 . Patient significant , uncontrolled concomitant infection and/or severe diarrhea , vomit , active peptic ulcer . 9 . Patient participate participate another clinical study and/or take take investigational drug past 28 day . 10 . Other reason depend assessment physician ( MMF give patient severe persistent hypersplenism ( WBC &lt; 3.500/ml , platelet &lt; 50.000/ml ) Informed Consent : Patient , give write consent participation study fulfil inclusion exclusion criterion , include study . After inclusion study , patient may withdraw time reason . Follow-up : ( time one patient observation ) -12 month Number center : 1 Number patient : 40 Indication : - Primary Liver transplantation Duration study : 36 month Enrollment period : 18 month</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Subjects meet follow criterion eligible study : 1 . Male female patient , old 18 year old . 2 . Primary liver transplantation 3 . Patient capable understand purpose risk study inform orally write give informed consent Subjects meet one follow criterion eligible study : 1 . Female patient pregnant breast feed 2 . Patients &gt; 18 year old 3 . Combined liverkidney transplantation 4 . Recipient second liver graft 5 . Patients allergic , hypersensitive intolerant HCO60 structurally related compound , macrolide antibiotic tacrolimus . 6 . Patients know HIVanamnesis 7 . Patient require ongoing dose systemic immunosuppressive drug study entry another indication prophylaxis liver graft rejection 8 . Patient significant , uncontrolled concomitant infection and/or severe diarrhoea , vomit , active peptic ulcer . 9 . Patient participate participate another clinical study and/or take take investigational drug past 28 day . 10 . Other reason depend assessment physician ( MMF give patient severe persistent hypersplenism ( WBC &lt; 3.500/ml , platelet &lt; 50.000/ml )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>immunosuppression ,</keyword>
	<keyword>steroid avoidance ,</keyword>
	<keyword>liver transplantation ,</keyword>
	<keyword>child</keyword>
</DOC>